Navigation Links
First Alzheimer’s Disease Gene Therapy Human Study Provided by Maximum Life Foundation, Offers 10 Free Therapies for Qualifying Patients
Date:12/30/2019

Cure Now ? Instead of Palliative Care

According to the Alzheimer’s Association:

  •     Alzheimer's disease is the 6th leading cause of death in the United States.
  •     More than 16 million Americans provide unpaid care for people with Alzheimer's or other dementia.
  •     These caregivers provided an estimated 18.5 billion hours of care valued at nearly $234 billion.
  •     Between 2000 and 2017 deaths from heart disease have decreased 9% while deaths from Alzheimer's have increased 145%.
  •     1 in 3 seniors dies with Alzheimer's or another dementia. It kills more than breast cancer and prostate cancer combined.

Alzheimer's costs Americans $277 billion a year – and rising. Sharp increases in Alzheimer's disease cases, deaths and costs are stressing the U.S. healthcare system and caregivers. About 5.7 million Americans have Alzheimer's disease. To date, no one has survived it.

Improvements of AD symptoms and the recovery of normal brain functions have been demonstrated in-vivo in mouse experiments, and in-vitro in human cell experiments through the rejuvenation of microglia (the brain’s first line of defense against infection) and neurons as well as stimulating mitochondrial function using the telomerase reverse transcriptase (TERT) protein.

One human patient received a lower dose therapy in August 2018 with no adverse side effects. To date, the patient’s disease has not progressed. MaxLife hopes to see symptom reversals in the next patients.

“If we can prove a benefit to patients that have no other option now, we can potentially treat Alzheimer’s Disease in people in early to mid-stage Alzheimer’s, finally creating effective medicine at the cellular level,” states Kekich. “If successful, this treatment could potentially be used on other diseases such as Parkinson’s and ALS.”

The unique difference is developing treatments against the cellular degeneration caused by aging as the root cause of most major diseases. Studies have proven aging is the leading risk factor for many life-threatening diseases, including Alzheimer's.

With a world class Scientific Advisory Board, MaxLife is ready to push forward into practical solutions. A gene therapy facilitator, Integrated Health Systems plans to treat other adult aging-related diseases with no previous cure such as Sarcopenia, Atherosclerosis, Chronic Kidney Disease (CKD)… and even aging itself with gene therapies.

“This technology could halt many of the big age associated killers in industrialized countries’” states Kekich. “Compassionate care helps patients with no other option to get access to experimental therapies that may benefit both themselves and society as a whole.”

MaxLife also seeks grants and donations for human gene therapy studies for atherosclerosis, sarcopenia and chronic kidney disease as well as for human aging. The protocols have already been developed. Please Click Here and scroll to the bottom of the page to see how to donate.

To apply for a free therapy or for more information, see http://www.maxlife.org/alzheimers-disease/ and https://maxlife.org/how-to-register-and-qualify-for-the-alzheimers-human-study/.

For Further Information, Contact: David Kekich, CEO Maximum Life Foundation.
Maximum Life Foundation is a 501(c)(3) Not-For-Profit corporation founded in 1999.
Tax I.D. #31-1656405. David A. Kekich Tel. #949-706-2468. Info@MaxLife.org

Read the full story at https://www.prweb.com/releases/first_alzheimers_disease_gene_therapy_human_study_provided_by_maximum_life_foundation_offers_10_free_therapies_for_qualifying_patients/prweb16809113.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Personalized Stem Cells, Inc. Announces First Patients Treated in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
2. Burlington Medical Develops the First-of-Its-Kind Radiation Protection Garment Exclusively for Women
3. The first International Sigma Anti-Bonding Calcium Symposium (ISACS 2019) by CBHI
4. Personalized Stem Cells, Inc. Announces First Patients Enrolled in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
5. Deep Science Ventures Launches Europe’s First Venture-Building Programme for Food & Agriculture
6. VetStem Biopharma Secures FDA Approval of First Human IND for its Subsidiary, Personalized Stem Cells, Inc.
7. Landsec and Spartan Bioscience Trial the World’s First On-Site Legionella DNA Test in the UK
8. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
9. McLeod Cancer Center First in the State of South Carolina to Achieve International Radiosurgery Certification
10. Draper Hosts First MassMEDIC Women in MedTech Networking and Leadership Forum Event of 2019
11. SpineFrontier's® First SacroFUSE® and NanoFUSE Case Performed in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... WORCESTER, Mass. (PRWEB) , ... December 10, 2019 ... ... and India has shown that probiotic yeasts derived from food are able to ... that are responsible for life-threatening infections in hospitalized and immune-compromised individuals, including the ...
(Date:12/4/2019)... ... December 03, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today ... (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate ...
(Date:11/27/2019)... ... , ... Though the forecast for the Thanksgiving holiday might look a bit ... hit the roads and the skies. It’s a new personal recipe organizer app called ... a simple design, mouth-watering pictures of food, an optional social component and an easy-to-navigate ...
Breaking Biology News(10 mins):
(Date:1/8/2020)... ... January 08, 2020 , ... ... helps couples and individuals grow their family, has announced that five of their ... Castle Connolly. Since 1991, the renowned publishing company Castle Connolly has ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... announced its expansion into whole-home smart lighting with two new products: the Brilliant ... the ability for homeowners and homebuilders to affordably add high-end smart lighting to ...
(Date:12/30/2019)... ... December 30, 2019 , ... ... leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries ... CFR Part 11 compliant software program specific to the custom-built helium leak testing ...
(Date:12/18/2019)... ... December 17, 2019 , ... Innovative Health, Inc. ... Electrophysiology (EP) devices since the company’s inception in 2016. This marks a record ... Johnson & Johnson company) have received 2 and 4 EP device clearances, respectively, ...
Breaking Biology Technology: